<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586169</url>
  </required_header>
  <id_info>
    <org_study_id>CNAM/AZIVAL/01</org_study_id>
    <secondary_id>0958/FMPOS</secondary_id>
    <nct_id>NCT01586169</nct_id>
  </id_info>
  <brief_title>Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination</brief_title>
  <acronym>AZIVAL</acronym>
  <official_title>A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Appui à la lutte contre la Maladie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Trachoma Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d'Appui à la lutte contre la Maladie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the triple co administration of&#xD;
      albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that&#xD;
      consists to treat with albendazole plus ivermectin together and a week later to treat with&#xD;
      azithromycin in areas co endemic for lymphatic filariasis and trachoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infectious diseases such as trachoma and lymphatic filariasis are public health problems in&#xD;
      regions of Africa and Asia. Elimination programs exist for the two diseases, and their&#xD;
      treatment by different groups of health workers is both costly and inefficient.&#xD;
&#xD;
      Thus, a study evaluating the safety and feasibility of an integrated mass treatment of&#xD;
      trachoma and lymphatic filariasis with azithromycin associated with albendazole and&#xD;
      ivermectin was instituted in 4 villages of the region of Sikasso in Mali (West Africa) co&#xD;
      endemic for lymphatic filariasis and trachoma.&#xD;
&#xD;
      It was an open label randomized clusters type on the assessment of the safety of the triple&#xD;
      co administration of azithromycin, ivermectin and albendazole (experimental regimen) as&#xD;
      compared to the administration of the co administration of albendazole plus ivermectin&#xD;
      followed by the that of azithromycin a week later (current standard recommended regimen)&#xD;
      within subjects of 5 to 65 years old, willing and able to swallow the study drugs.&#xD;
&#xD;
      Clinical evaluation of adverse events in all study participants was done on day 0, day 8, and&#xD;
      day 15 after the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the incidence of adverse events associated with the mass triple drug administration</measure>
    <time_frame>From Day 0 to Day 15 post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish the incidence of serious adverse events associated with the mass triple drug administration</measure>
    <time_frame>From Day 0 to Day 15 post treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3000</enrollment>
  <condition>Parasitic Diseases</condition>
  <condition>Bacterial Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple co administration at once of the combination of Albendazole + ivermectin + azithromycin</intervention_name>
    <description>Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once</description>
    <other_name>Albendazole</other_name>
    <other_name>Mectizan</other_name>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have been residing in the village for at least three months;&#xD;
&#xD;
          -  Must be 90 cm tall or more;&#xD;
&#xD;
          -  Must be between 5 years and 65 years of age;&#xD;
&#xD;
          -  Must not be pregnant;&#xD;
&#xD;
          -  Must not be lactating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under 5 years of age or less than 90 cm in height;&#xD;
&#xD;
          -  Subjects over 65 years of age;&#xD;
&#xD;
          -  Subjects who cannot swallow tablets;&#xD;
&#xD;
          -  Subjects who are sick and bedridden;&#xD;
&#xD;
          -  Pregnant women (clinical appreciation in the study);&#xD;
&#xD;
          -  Lactating women;&#xD;
&#xD;
          -  History of allergies to the drugs being studied (azithromycin, ivermectin,&#xD;
             albendazole).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samba O Sow, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNAM, Mali</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre National D'Appui a la lutte contre la Maladie</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Albendazole</keyword>
  <keyword>Ivermectin</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Lymphatic filariasis</keyword>
  <keyword>Trachoma</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Trachoma</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

